C. Palmer

发表

Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain expos

Wei Liu, Huichun Zhu, Dac Dinh, 2014, Journal of medicinal chemistry.

Structural modifications of a 3-methoxy-2-aminopyridine compound to reduce potential for mutagenicity and time-dependent drug-drug interaction.

D. Bouzida, M. Pairish, S. Yamazaki, 2012, Bioorganic & medicinal chemistry letters.

Discovery of (10R)-7-Amino-12-Fluoro-2,10,16-Trimethyl-15-Oxo-10,15,16,17-Tetrahydro-2H-8,4-(Metheno)Pyrazolo[4,3-H][2,5,11]Benzoxadiazacyclotetradecine-3-Carbonitrile (Pf-06463922), a Macrocyclic Inhibitor of Alk/Ros1 with Pre-Clinical Brain Exposure and Broad Spectrum Potency Against Alk-Resistant

Huichun Zhu, Benjamin J. Burke, John Charles Kath, 2014 .

Structure-based design of lipophilic quinazoline inhibitors of thymidylate synthase.

D. Matthews, C. Janson, K. Appelt, 1996, Journal of medicinal chemistry.

AG2034: a novel inhibitor of glycinamide ribonucleotide formyltransferase

E. Howland, R. Jackson, S. Margosiak, 2004, Investigational New Drugs.

Protein structure-based design, synthesis, and biological evaluation of 5-thia-2,6-diamino-4(3H)-oxopyrimidines: potent inhibitors of glycinamide ribonucleotide transformylase with potent cell growth inhibition.

C. Janson, C. Bartlett, M. Varney, 1997, Journal of medicinal chemistry.

Crystal-structure-based design and synthesis of novel C-terminal inhibitors of HIV protease.

K. Appelt, V. Kalish, M. Varney, 1994, Journal of medicinal chemistry.

Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib.

N. Sach, Hong Shen, M. McTigue, 2014, Journal of medicinal chemistry.

Epithelial Tissue Hyperplasia Induced by the RAF Inhibitor PF-04880594 Is Attenuated by a Clinically Well-Tolerated Dose of the MEK Inhibitor PD-0325901

S. Yamazaki, D. Wojciechowicz, S. Bagrodia, 2012, Molecular Cancer Therapeutics.

Synthesis and biological evaluation of novel 2,6-diaminobenz[cd]indole inhibitors of thymidylate synthase using the protein structure as a guide.

C. Janson, C. Bartlett, M. Varney, 1995, Journal of medicinal chemistry.

Crystal-structure-based design and synthesis of benz[cd]indole-containing inhibitors of thymidylate synthase.

C A Morse, R. Bacquet, C. Bartlett, 1992, Journal of medicinal chemistry.

AG-024322 is a multi-targeted CDK inhibitor with potent antitumor activity in vivo

Gennady M Verkhivker, D. Knighton, C. Lewis, 2005 .

AG-024322 is a potent and selective multi-targeted CDK inhibitor with broad spectrum anti-proliferative activity

Gennady M Verkhivker, D. Knighton, C. Lewis, 2005 .

Abstract PR10: Is CNS availability for oncology a no-brainer? Discovery of PF-06463922, a novel small molecule inhibitor of ALK/ROS1 with preclinical brain availability and broad spectrum potency against ALK-resistant mutations.

N. Sach, M. McTigue, H. Zou, 2013 .

Discovery of (10R)-7-Amino-12-Fluoro-2,10,16-Trimethyl-15-Oxo-10,15,16,17-Tetrahydro-2H-8,4-(Metheno)Pyrazolo[4,3-H][2,5,11]Benzoxadiazacyclotetradecine-3-Carbonitrile (Pf-06463922), a Macrocyclic Inhibitor of Alk/Ros1 with Pre-Clinical Brain Exposure and Broad Spectrum Potency Against Alk-Resistant

N. Sach, H. Zou, R. Kania, 2014 .